{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:37:12Z","timestamp":1782236232325,"version":"3.54.5"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["COVID-2020C2-10803"],"award-info":[{"award-number":["COVID-2020C2-10803"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI 042007"],"award-info":[{"award-number":["R01 AI 042007"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["T32HS000063"],"award-info":[{"award-number":["T32HS000063"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Implement Sci Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Implementation research generally assumes established evidence-based practices and prior piloting of implementation strategies, which may not be feasible during a public health emergency. We describe the use of a simulation model of the effectiveness of COVID-19 mitigation strategies to inform a stakeholder-engaged process of rapidly designing a tailored intervention and implementation strategy for individuals with serious mental illness (SMI) and intellectual\/developmental disabilities (ID\/DD) in group homes in a hybrid effectiveness-implementation randomized trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used a validated dynamic microsimulation model of COVID-19 transmission and disease in late 2020\/early 2021 to determine the most effective strategies to mitigate infections among Massachusetts group home staff and residents. Model inputs were informed by data from stakeholders, public records, and published literature. We assessed different prevention strategies, iterated over time with input from multidisciplinary stakeholders and pandemic evolution, including varying symptom screening, testing frequency, isolation, contact-time, use of personal protective equipment, and vaccination. Model outcomes included new infections in group home residents, new infections in group home staff, and resident hospital days. Sensitivity analyses were performed to account for parameter uncertainty. Results of the simulations informed a stakeholder-engaged process to select components of a tailored best practice intervention and implementation strategy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The largest projected decrease in infections was with initial vaccination, with minimal benefit for additional routine testing. The initial level of actual vaccination in the group homes was estimated to reduce resident infections by 72.4% and staff infections by 55.9% over the 90-day time horizon. Increasing resident and staff vaccination uptake to a target goal of 90% further decreased resident infections by 45.2% and staff infections by 51.3%. Subsequent simulated removal of masking led to a 6.5% increase in infections among residents and 3.2% among staff. The simulation model results were presented to multidisciplinary stakeholders and policymakers to inform the \u201cTailored Best Practice\u201d package for the hybrid effectiveness-implementation trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Vaccination and decreasing vaccine hesitancy among staff were predicted to have the greatest impact in mitigating COVID-19 risk in vulnerable populations of group home residents and staff. Simulation modeling was effective in rapidly informing the selection of the prevention and implementation strategy in a hybrid effectiveness-implementation trial. Future implementation may benefit from this approach when rapid deployment is necessary in the absence of data on tailored interventions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov NCT04726371<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43058-024-00593-w","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T10:02:51Z","timestamp":1719223371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Using simulation modeling to inform intervention and implementation selection in a rapid stakeholder-engaged hybrid effectiveness-implementation randomized trial"],"prefix":"10.1186","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0522-2836","authenticated-orcid":false,"given":"Jessica E.","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma M.","family":"Shebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Losina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie H.","family":"Levison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Donelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Trieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Panella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooyan","family":"Kazemian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Skotko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth A.","family":"Freedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"593_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-publhealth-110717-045850","volume":"39","author":"DA Chambers","year":"2018","unstructured":"Chambers DA. Commentary: increasing the connectivity between implementation science and public health: advancing methodology, evidence integration, and sustainability. Annu Rev Public Health. 2018;39:1\u20134. https:\/\/doi.org\/10.1146\/annurev-publhealth-110717-045850.","journal-title":"Annu Rev Public Health"},{"issue":"5","key":"593_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/wvn.12403","volume":"16","author":"A Westerlund","year":"2019","unstructured":"Westerlund A, Sundberg L, Nilsen P. Implementation of implementation science knowledge: the research-practice gap paradox. Worldviews Evid Based Nurs. 2019;16(5):332\u20134. https:\/\/doi.org\/10.1111\/wvn.12403.","journal-title":"Worldviews Evid Based Nurs"},{"key":"593_CR3","doi-asserted-by":"publisher","first-page":"112376","DOI":"10.1016\/j.psychres.2019.04.025","volume":"283","author":"MS Bauer","year":"2020","unstructured":"Bauer MS, Kirchner J. Implementation science: what is it and why should I care? Psychiatry Res. 2020;283:112376. https:\/\/doi.org\/10.1016\/j.psychres.2019.04.025.","journal-title":"Psychiatry Res"},{"issue":"3","key":"593_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/MLR.0b013e3182408812","volume":"50","author":"GM Curran","year":"2012","unstructured":"Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012;50(3):217\u201326. https:\/\/doi.org\/10.1097\/MLR.0b013e3182408812.","journal-title":"Med Care"},{"key":"593_CR5","doi-asserted-by":"publisher","first-page":"1053496","DOI":"10.3389\/frhs.2022.1053496","volume":"2","author":"GM Curran","year":"2022","unstructured":"Curran GM, Landes SJ, McBain SA, et al. Reflections on 10 years of effectiveness-implementation hybrid studies. Front Health Serv. 2022;2:1053496. https:\/\/doi.org\/10.3389\/frhs.2022.1053496.","journal-title":"Front Health Serv"},{"issue":"3","key":"593_CR6","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s13142-017-0495-z","volume":"7","author":"MS Goodman","year":"2017","unstructured":"Goodman MS, Sanders Thompson VL. The science of stakeholder engagement in research: classification, implementation, and evaluation. Transl Behav Med. 2017;7(3):486\u201391. https:\/\/doi.org\/10.1007\/s13142-017-0495-z.","journal-title":"Transl Behav Med"},{"issue":"8","key":"593_CR7","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s11606-012-2037-1","volume":"27","author":"TW Concannon","year":"2012","unstructured":"Concannon TW, Meissner P, Grunbaum JA, et al. A new taxonomy for stakeholder engagement in patient-centered outcomes research. J Gen Intern Med. 2012;27(8):985\u201391. https:\/\/doi.org\/10.1007\/s11606-012-2037-1.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"593_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10488-010-0327-7","volume":"38","author":"GA Aarons","year":"2011","unstructured":"Aarons GA, Hurlburt M, Horwitz SM. Advancing a conceptual model of evidence-based practice implementation in public service sectors. Adm Policy Ment Health Ment Health Serv Res. 2011;38(1):4\u201323. https:\/\/doi.org\/10.1007\/s10488-010-0327-7.","journal-title":"Adm Policy Ment Health Ment Health Serv Res"},{"issue":"12","key":"593_CR9","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1007\/s11606-014-2878-x","volume":"29","author":"TW Concannon","year":"2014","unstructured":"Concannon TW, Fuster M, Saunders T, et al. A systematic review of stakeholder engagement in comparative effectiveness and patient-centered outcomes research. J Gen Intern Med. 2014;29(12):1692\u2013701. https:\/\/doi.org\/10.1007\/s11606-014-2878-x.","journal-title":"J Gen Intern Med"},{"key":"593_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.schres.2020.05.054","volume":"222","author":"K Hamada","year":"2020","unstructured":"Hamada K, Fan X. The impact of COVID-19 on individuals living with serious mental illness. Schizophr Res. 2020;222:3\u20135. https:\/\/doi.org\/10.1016\/j.schres.2020.05.054.","journal-title":"Schizophr Res"},{"key":"593_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jpsychires.2020.09.020","volume":"131","author":"S Chen","year":"2020","unstructured":"Chen S, Jones PB, Underwood BR, et al. The early impact of COVID-19 on mental health and community physical health services and their patients\u2019 mortality in Cambridgeshire and Peterborough. UK J Psychiatr Res. 2020;131:244\u201354. https:\/\/doi.org\/10.1016\/j.jpsychires.2020.09.020.","journal-title":"UK J Psychiatr Res"},{"issue":"3","key":"593_CR12","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/schbul\/sbaa158","volume":"47","author":"G Fond","year":"2021","unstructured":"Fond G, Pauly V, Leone M, et al. Disparities in intensive care unit admission and mortality among patients with schizophrenia and COVID-19: a national cohort study. Schizophr Bull. 2021;47(3):624\u201334. https:\/\/doi.org\/10.1093\/schbul\/sbaa158.","journal-title":"Schizophr Bull"},{"issue":"2","key":"593_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.encep.2020.07.003","volume":"47","author":"G Fond","year":"2021","unstructured":"Fond G, Pauly V, Orleans V, et al. Increased in-hospital mortality from COVID-19 in patients with schizophrenia. L\u2019Enc\u00e9phale. 2021;47(2):89\u201395. https:\/\/doi.org\/10.1016\/j.encep.2020.07.003.","journal-title":"L\u2019Enc\u00e9phale"},{"issue":"4","key":"593_CR14","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jamapsychiatry.2020.4442","volume":"78","author":"K Nemani","year":"2021","unstructured":"Nemani K, Li C, Olfson M, et al. Association of psychiatric disorders with mortality among patients with COVID-19. JAMA Psychiat. 2021;78(4):380\u20136. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.4442.","journal-title":"JAMA Psychiat"},{"key":"593_CR15","doi-asserted-by":"crossref","unstructured":"Wang Q, Xu R, Volkow ND. Increased risk of COVID\u201019 infection and mortality in people with mental disorders: analysis from electronic health records in the United States - Wang - 2021 - World Psychiatry - Wiley Online Library. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/wps.20806. Accessed 6 July 2022.","DOI":"10.1002\/wps.20806"},{"issue":"4","key":"593_CR16","doi-asserted-by":"publisher","first-page":"572","DOI":"10.7326\/M20-4986","volume":"174","author":"AK Clift","year":"2021","unstructured":"Clift AK, Coupland CAC, Keogh RH, Hemingway H, Hippisley-Cox J. COVID-19 mortality risk in down syndrome: results from a cohort study of 8 million adults. Ann Intern Med. 2021;174(4):572\u20136. https:\/\/doi.org\/10.7326\/M20-4986.","journal-title":"Ann Intern Med"},{"issue":"5","key":"593_CR17","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s10072-021-05091-8","volume":"42","author":"A Emami","year":"2021","unstructured":"Emami A, Javanmardi F, Akbari A, Asadi-Pooya AA. COVID-19 in patients with Down syndrome. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2021;42(5):1649\u201352. https:\/\/doi.org\/10.1007\/s10072-021-05091-8.","journal-title":"Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"key":"593_CR18","doi-asserted-by":"publisher","first-page":"100769","DOI":"10.1016\/j.eclinm.2021.100769","volume":"33","author":"A H\u00fcls","year":"2021","unstructured":"H\u00fcls A, Costa ACS, Dierssen M, et al. Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey. EClinicalMedicine. 2021;33:100769. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100769.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"593_CR19","doi-asserted-by":"publisher","first-page":"e2112862","DOI":"10.1001\/jamanetworkopen.2021.12862","volume":"4","author":"SD Landes","year":"2021","unstructured":"Landes SD, Turk MA, Damiani MR, Proctor P, Baier S. Risk factors associated with COVID-19 outcomes among people with intellectual and developmental disabilities receiving residential services. JAMA Netw Open. 2021;4(6):e2112862. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.12862.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"593_CR20","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1176\/appi.ps.202000244","volume":"71","author":"SJ Bartels","year":"2020","unstructured":"Bartels SJ, Baggett TP, Freudenreich O, Bird BL. COVID-19 emergency reforms in Massachusetts to support behavioral health care and reduce mortality of people with serious mental illness. Psychiatr Serv. 2020;71(10):1078\u201381. https:\/\/doi.org\/10.1176\/appi.ps.202000244.","journal-title":"Psychiatr Serv"},{"issue":"4","key":"593_CR21","doi-asserted-by":"publisher","first-page":"100969","DOI":"10.1016\/j.dhjo.2020.100969","volume":"13","author":"SD Landes","year":"2020","unstructured":"Landes SD, Turk MA, Formica MK, McDonald KE, Stevens JD. COVID-19 outcomes among people with intellectual and developmental disability living in residential group homes in New York State. Disabil Health J. 2020;13(4):100969. https:\/\/doi.org\/10.1016\/j.dhjo.2020.100969.","journal-title":"Disabil Health J"},{"key":"593_CR22","doi-asserted-by":"publisher","unstructured":"Sheehan R, Dalton-Locke C, Ali A, Vera San Juan N, Totsika V, Hassiotis A. Effects of the COVID-19 pandemic on mental healthcare and services: results of a UK survey of front-line staff working with people with intellectual disability and\/or autism. BJPsych Bull. 2021:1\u20137. https:\/\/doi.org\/10.1192\/bjb.2021.52.","DOI":"10.1192\/bjb.2021.52"},{"issue":"9","key":"593_CR23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamapsychiatry.2020.0894","volume":"77","author":"BG Druss","year":"2020","unstructured":"Druss BG. Addressing the COVID-19 pandemic in populations with serious mental illness. JAMA Psychiat. 2020;77(9):891\u20132. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.0894.","journal-title":"JAMA Psychiat"},{"issue":"5","key":"593_CR24","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S2468-2667(20)30076-1","volume":"5","author":"R Armitage","year":"2020","unstructured":"Armitage R, Nellums LB. The COVID-19 response must be disability inclusive. Lancet Public Health. 2020;5(5):e257. https:\/\/doi.org\/10.1016\/S2468-2667(20)30076-1.","journal-title":"Lancet Public Health"},{"issue":"3","key":"593_CR25","doi-asserted-by":"publisher","first-page":"20com13412","DOI":"10.4088\/JCP.20com13412","volume":"81","author":"AK Shinn","year":"2020","unstructured":"Shinn AK, Viron M. Perspectives on the COVID-19 pandemic and individuals with serious mental illness. J Clin Psychiatry. 2020;81(3):20com13412. https:\/\/doi.org\/10.4088\/JCP.20com13412.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"593_CR26","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jamda.2020.03.024","volume":"21","author":"S Zimmerman","year":"2020","unstructured":"Zimmerman S, Sloane PD, Katz PR, Kunze M, O\u2019Neil K, Resnick B. The need to include assisted living in responding to the COVID-19 pandemic. J Am Med Dir Assoc. 2020;21(5):572\u20135. https:\/\/doi.org\/10.1016\/j.jamda.2020.03.024.","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"593_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4269\/ajtmh.20-0391","volume":"103","author":"J Solis","year":"2020","unstructured":"Solis J, Franco-Paredes C, Henao-Mart\u00ednez AF, Krsak M, Zimmer SM. Structural vulnerability in the U.S. revealed in three waves of COVID-19. Am J Trop Med Hyg. 2020;103(1):25\u20137. https:\/\/doi.org\/10.4269\/ajtmh.20-0391.","journal-title":"Am J Trop Med Hyg"},{"issue":"8","key":"593_CR28","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1001\/jamainternmed.2020.2224","volume":"180","author":"GY Jenq","year":"2020","unstructured":"Jenq GY, Mills JP, Malani PN. Preventing COVID-19 in assisted living facilities-a balancing act. JAMA Intern Med. 2020;180(8):1106\u20137. https:\/\/doi.org\/10.1001\/jamainternmed.2020.2224.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"593_CR29","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","volume":"72","author":"ER Walker","year":"2015","unstructured":"Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiat. 2015;72(4):334\u201341. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.2502.","journal-title":"JAMA Psychiat"},{"issue":"5","key":"593_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S2215-0366(17)30111-6","volume":"4","author":"SJ Bartels","year":"2017","unstructured":"Bartels SJ, DiMilia P. Why serious mental illness should be designated a health disparity and the paradox of ethnicity. Lancet Psychiatry. 2017;4(5):351\u20132. https:\/\/doi.org\/10.1016\/S2215-0366(17)30111-6.","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"593_CR31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.genhosppsych.2015.03.004","volume":"37","author":"EM Janssen","year":"2015","unstructured":"Janssen EM, McGinty EE, Azrin ST, Juliano-Bult D, Daumit GL. Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness. Gen Hosp Psychiatry. 2015;37(3):199\u2013222. https:\/\/doi.org\/10.1016\/j.genhosppsych.2015.03.004.","journal-title":"Gen Hosp Psychiatry"},{"issue":"5","key":"593_CR32","doi-asserted-by":"publisher","first-page":"2000547","DOI":"10.1183\/13993003.00547-2020","volume":"55","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. https:\/\/doi.org\/10.1183\/13993003.00547-2020.","journal-title":"Eur Respir J"},{"issue":"9","key":"593_CR33","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1093\/ntr\/ntaa059","volume":"22","author":"I Berlin","year":"2020","unstructured":"Berlin I, Thomas D, Le Faou AL, Cornuz J. COVID-19 and smoking. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2020;22(9):1650\u20132. https:\/\/doi.org\/10.1093\/ntr\/ntaa059.","journal-title":"Nicotine Tob Res Off J Soc Res Nicotine Tob"},{"issue":"1","key":"593_CR34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ajmg.a.38512","volume":"176","author":"GT Capone","year":"2018","unstructured":"Capone GT, Chicoine B, Bulova P, et al. Co-occurring medical conditions in adults with Down syndrome: a systematic review toward the development of health care guidelines. Am J Med Genet A. 2018;176(1):116\u201333. https:\/\/doi.org\/10.1002\/ajmg.a.38512.","journal-title":"Am J Med Genet A"},{"issue":"7","key":"593_CR35","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1002\/ajmg.a.61604","volume":"182","author":"G Capone","year":"2020","unstructured":"Capone G, Stephens M, Santoro S, et al. Co-occurring medical conditions in adults with Down syndrome: a systematic review toward the development of health care guidelines. Part II. Am J Med Genet A. 2020;182(7):1832\u201345. https:\/\/doi.org\/10.1002\/ajmg.a.61604.","journal-title":"Am J Med Genet A"},{"issue":"2","key":"593_CR36","doi-asserted-by":"publisher","first-page":"e018292","DOI":"10.1136\/bmjopen-2017-018292","volume":"8","author":"D Kinnear","year":"2018","unstructured":"Kinnear D, Morrison J, Allan L, Henderson A, Smiley E, Cooper SA. Prevalence of physical conditions and multimorbidity in a cohort of adults with intellectual disabilities with and without Down syndrome: cross-sectional study. BMJ Open. 2018;8(2):e018292. https:\/\/doi.org\/10.1136\/bmjopen-2017-018292.","journal-title":"BMJ Open"},{"issue":"3","key":"593_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/jar.12417","volume":"31","author":"L O\u2019Leary","year":"2018","unstructured":"O\u2019Leary L, Cooper SA, Hughes-McCormack L. Early death and causes of death of people with intellectual disabilities: a systematic review. J Appl Res Intellect Disabil JARID. 2018;31(3):325\u201342. https:\/\/doi.org\/10.1111\/jar.12417.","journal-title":"J Appl Res Intellect Disabil JARID"},{"key":"593_CR38","unstructured":"Hakim D. \u2018It\u2019s hit our front door\u2019: homes for the disabled see a surge of Covid-19. The New York Times; 2020. https:\/\/www.nytimes.com\/2020\/04\/08\/nyregion\/coronavirus-disabilities-group-homes.html. Accessed 5 Apr 2023."},{"key":"593_CR39","doi-asserted-by":"publisher","unstructured":"Levison JH, Krane D, Donelan K, et al. Best practices to reduce COVID-19 in group homes for individuals with serious mental illness and intellectual and developmental disabilities: protocol for a hybrid type 1 effectiveness-implementation cluster randomized trial. Contemp Clin Trials. 2022:107053. https:\/\/doi.org\/10.1016\/j.cct.2022.107053.","DOI":"10.1016\/j.cct.2022.107053"},{"issue":"12","key":"593_CR40","doi-asserted-by":"publisher","first-page":"e2028195","DOI":"10.1001\/jamanetworkopen.2020.28195","volume":"3","author":"TP Baggett","year":"2020","unstructured":"Baggett TP, Scott JA, Le MH, et al. Clinical outcomes, costs, and cost-effectiveness of strategies for adults experiencing sheltered homelessness during the COVID-19 pandemic. JAMA Netw Open. 2020;3(12):e2028195. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.28195.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"593_CR41","doi-asserted-by":"publisher","first-page":"472","DOI":"10.7326\/M20-6558","volume":"174","author":"E Losina","year":"2021","unstructured":"Losina E, Leifer V, Millham L, et al. College campuses and COVID-19 mitigation: clinical and economic value. Ann Intern Med. 2021;174(4):472\u201383. https:\/\/doi.org\/10.7326\/M20-6558.","journal-title":"Ann Intern Med"},{"issue":"9","key":"593_CR42","doi-asserted-by":"publisher","first-page":"e2908","DOI":"10.1093\/cid\/ciaa1418","volume":"73","author":"AM Neilan","year":"2020","unstructured":"Neilan AM, Losina E, Bangs AC, et al. Clinical impact, costs, and cost-effectiveness of expanded severe acute respiratory syndrome coronavirus 2 testing in Massachusetts. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020;73(9):e2908\u201317. https:\/\/doi.org\/10.1093\/cid\/ciaa1418.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"593_CR43","unstructured":"COVID-19 response reporting | Mass.gov. https:\/\/www.mass.gov\/info-details\/covid-19-response-reporting. Accessed 2 Aug 2021."},{"key":"593_CR44","unstructured":"U.S. Census Bureau QuickFacts. Massachusetts. https:\/\/www.census.gov\/quickfacts\/MA. Accessed 21 Dec 2022."},{"key":"593_CR45","unstructured":"CDC. Healthcare workers. Centers for Disease Control and Prevention; 2020. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/planning-scenarios.html. Accessed 21 Dec 2022."},{"issue":"8","key":"593_CR46","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1093\/cid\/ciaa450","volume":"71","author":"W Li","year":"2020","unstructured":"Li W, Zhang B, Lu J, et al. Characteristics of household transmission of COVID-19. Clin Infect Dis. 2020;71(8):1943\u20136. https:\/\/doi.org\/10.1093\/cid\/ciaa450.","journal-title":"Clin Infect Dis"},{"issue":"28","key":"593_CR47","doi-asserted-by":"publisher","first-page":"933","DOI":"10.15585\/mmwr.mm6928e3","volume":"69","author":"KA Fisher","year":"2020","unstructured":"Fisher KA, Barile JP, Guerin RJ, et al. Factors associated with cloth face covering use among adults during the COVID-19 pandemic \u2014 United States, April and May 2020. MMWR Morb Mortal Wkly Rep. 2020;69(28):933\u20137. https:\/\/doi.org\/10.15585\/mmwr.mm6928e3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"27","key":"593_CR48","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2034577.","journal-title":"N Engl J Med"},{"issue":"4","key":"593_CR49","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/M20-1495","volume":"173","author":"LM Kucirka","year":"2020","unstructured":"Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020;173(4):262\u20137. https:\/\/doi.org\/10.7326\/M20-1495.","journal-title":"Ann Intern Med"},{"key":"593_CR50","unstructured":"CDC. Health Departments. Centers for Disease Control and Prevention. 2020. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/php\/contact-tracing\/contact-tracing-plan\/appendix.html. Accessed 22 Dec 2022."},{"key":"593_CR51","unstructured":"Massachusetts COVID-19 community mobility report. Google; 2021. https:\/\/www.gstatic.com\/covid19\/mobility\/2021-02-02_US_Massachusetts_Mobility_Report_en.pdf."},{"issue":"4","key":"593_CR52","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/cid\/ciab517","volume":"74","author":"R Kahn","year":"2022","unstructured":"Kahn R, Holmdahl I, Reddy S, Jernigan J, Mina MJ, Slayton RB. Mathematical modeling to inform vaccination strategies and testing approaches for coronavirus disease 2019 (COVID-19) in nursing homes. Clin Infect Dis. 2022;74(4):597\u2013603. https:\/\/doi.org\/10.1093\/cid\/ciab517.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"593_CR53","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1086\/319223","volume":"32","author":"A David Paltiel","year":"2001","unstructured":"David Paltiel A, Goldie SJ, Losina E, et al. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus. Clin Infect Dis. 2001;32(5):783\u201393. https:\/\/doi.org\/10.1086\/319223.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"593_CR54","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13063-021-05112-z","volume":"22","author":"R Spies","year":"2021","unstructured":"Spies R, Siegfried N, Myers B, Grobbelaar SS. Concept and development of an interactive tool for trial recruitment planning and management. Trials. 2021;22(1):189. https:\/\/doi.org\/10.1186\/s13063-021-05112-z.","journal-title":"Trials"},{"issue":"8","key":"593_CR55","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1086\/521933","volume":"45","author":"BR Schackman","year":"2007","unstructured":"Schackman BR, Scott CA, Sax PE, et al. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis. 2007;45(8):1062\u201370. https:\/\/doi.org\/10.1086\/521933.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"593_CR56","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jbi.2008.04.008","volume":"41","author":"I Abbas","year":"2008","unstructured":"Abbas I, Rovira J, Casanovas J, Greenfield T. Optimal design of clinical trials with computer simulation based on results of earlier trials, illustrated with a lipodystrophy trial in HIV patients. J Biomed Inform. 2008;41(6):1053\u201361. https:\/\/doi.org\/10.1016\/j.jbi.2008.04.008.","journal-title":"J Biomed Inform"},{"issue":"9","key":"593_CR57","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/QAD.0b013e32835221eb","volume":"26","author":"SB Lorenzana","year":"2012","unstructured":"Lorenzana SB, Hughes MD, Grinsztejn B, et al. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. AIDS. 2012;26(9):1083\u201393. https:\/\/doi.org\/10.1097\/QAD.0b013e32835221eb.","journal-title":"AIDS"},{"issue":"1","key":"593_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-publhealth-031816-044215","volume":"38","author":"CH Brown","year":"2017","unstructured":"Brown CH, Curran G, Palinkas LA, et al. An overview of research and evaluation designs for dissemination and implementation. Annu Rev Public Health. 2017;38(1):1\u201322. https:\/\/doi.org\/10.1146\/annurev-publhealth-031816-044215.","journal-title":"Annu Rev Public Health"},{"key":"593_CR59","doi-asserted-by":"publisher","first-page":"263348952110106","DOI":"10.1177\/26334895211010664","volume":"2","author":"W Huang","year":"2021","unstructured":"Huang W, Chang CH, Stuart EA, et al. Agent-based modeling for implementation research: an application to tobacco smoking cessation for persons with serious mental illness. Implement Res Pract. 2021;2:263348952110106. https:\/\/doi.org\/10.1177\/26334895211010664.","journal-title":"Implement Res Pract"},{"issue":"1","key":"593_CR60","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s43058-021-00218-6","volume":"2","author":"RC Sheldrick","year":"2021","unstructured":"Sheldrick RC, Cruden G, Schaefer AJ, Mackie TI. Rapid-cycle systems modeling to support evidence-informed decision-making during system-wide implementation. Implement Sci Commun. 2021;2(1):116. https:\/\/doi.org\/10.1186\/s43058-021-00218-6.","journal-title":"Implement Sci Commun"},{"issue":"11","key":"593_CR61","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/infdis\/jiac243","volume":"226","author":"MJ Siedner","year":"2022","unstructured":"Siedner MJ, Alba C, Fitzmaurice KP, et al. Cost-effectiveness of coronavirus disease 2019 vaccination in low- and middle-income countries. J Infect Dis. 2022;226(11):1887\u201396. https:\/\/doi.org\/10.1093\/infdis\/jiac243.","journal-title":"J Infect Dis"},{"issue":"1","key":"593_CR62","doi-asserted-by":"publisher","first-page":"6238","DOI":"10.1038\/s41467-021-26557-5","volume":"12","author":"KP Reddy","year":"2021","unstructured":"Reddy KP, Fitzmaurice KP, Scott JA, et al. Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa. Nat Commun. 2021;12(1):6238. https:\/\/doi.org\/10.1038\/s41467-021-26557-5.","journal-title":"Nat Commun"},{"issue":"2","key":"593_CR63","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1016\/S2214-109X(20)30452-6","volume":"9","author":"KP Reddy","year":"2021","unstructured":"Reddy KP, Shebl FM, Foote JHA, et al. Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa: a microsimulation modelling study. Lancet Glob Health. 2021;9(2):e120\u20139. https:\/\/doi.org\/10.1016\/S2214-109X(20)30452-6.","journal-title":"Lancet Glob Health"},{"issue":"23","key":"593_CR64","doi-asserted-by":"publisher","first-page":"e2115714119","DOI":"10.1073\/pnas.2115714119","volume":"119","author":"TY Lim","year":"2022","unstructured":"Lim TY, Stringfellow EJ, Stafford CA, et al. Modeling the evolution of the US opioid crisis for national policy development. Proc Natl Acad Sci. 2022;119(23):e2115714119. https:\/\/doi.org\/10.1073\/pnas.2115714119.","journal-title":"Proc Natl Acad Sci"}],"container-title":["Implementation Science Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43058-024-00593-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43058-024-00593-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43058-024-00593-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T10:06:42Z","timestamp":1719223602000},"score":1,"resource":{"primary":{"URL":"https:\/\/implementationsciencecomms.biomedcentral.com\/articles\/10.1186\/s43058-024-00593-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["593"],"URL":"https:\/\/doi.org\/10.1186\/s43058-024-00593-w","relation":{},"ISSN":["2662-2211"],"issn-type":[{"value":"2662-2211","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"assertion":[{"value":"30 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As detailed in the text, the study was approved by the Institutional Review Boards of MassGeneral Brigham, the Massachusetts Department of Developmental Services, and the Massachusetts Department of Mental Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Bartels reports receiving research grant funding from PCORI and NIH, and receives consulting fees as scientific co-director for a SAMHSA funded Center of Excellence for Behavioral Health Disparities in Aging at Rush University.Dr. Becker was supported by AHRQ grant number T32HS000063 as part of the Harvard-wide Pediatric Health Services Research Fellowship Program. Dr. Becker is a current recipient of the American Academy of Child and Adolescent Psychiatry (AACAP) Junior Investigator Award supported by AACAP and Industry Sponsors (Sunovion Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.).Dr. Donelan reports receiving funding from PCORI, American Cancer Society, Dartmouth College, and Brandeis University. She is an unpaid board member of Bridges Associates, Yarmouthport, MA.Dr. Freedberg reports receiving research grant funding from NIH.Dr. Fung reports receiving research grant funding from NIH and AHRQ.Dr. Levison reports receiving research grants from NIH and receives fees as a medical advisor to eMED, LLC.Dr. Skotko occasionally consults on the topic of Down syndrome through Gerson Lehrman Group. He receives remuneration from Down syndrome non-profit organizations for speaking engagements and associated travel expenses. In the past 2 years, Dr. Skotko received annual royalties from Woodbine House, Inc., for the publication of his book, Fasten Your Seatbelt: A Crash Course on Down Syndrome for Brothers and Sisters. Within the past 2 years, he has received research funding from AC Immune, and LuMind IDSC Down Syndrome Foundation to conduct clinical trials for people with Down syndrome. Dr. Skotko is occasionally asked to serve as an expert witness for legal cases where Down syndrome is discussed. Dr. Skotko serves in a non-paid capacity on the Honorary Board of Directors for the Massachusetts Down Syndrome Congress and the Professional Advisory Committee for the National Center for Prenatal and Postnatal Down Syndrome Resources. Dr. Skotko has a sister with Down syndrome.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}